Allarity Therapeutics, Inc. (ALLR) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Allarity Therapeutics, Inc. on September 14, 2026, covering events occurring on September 11, 2026. The Company is an emerging growth company incorporated in Delaware with its principal executive offices in Tarpon Springs, Florida. Its common stock trades on The Nasdaq Stock Market LLC under the symbol "ALLR."
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a corporate event rather than periodic financial performance data.
Material Changes
On September 11, 2026, the Company announced the formation of Allarity Acquisition Corp., a newly formed special purpose acquisition company (SPAC). Allarity Acquisition Corp. has publicly filed a Registration Statement on Form S-1 with the U.S. Securities and Exchange Commission relating to a proposed initial public offering of its units.
Guidance, Outlook, and Risks
The filing does not contain specific financial guidance, management commentary on future performance, or a detailed discussion of risks and contingencies beyond the announcement of the SPAC filing. The primary disclosure is the initiation of the IPO process for the new SPAC entity.
Investor Verification Checklist
- Verify the details of the proposed IPO for Allarity Acquisition Corp. via the attached Form S-1 Registration Statement.
- Review the full text of the press release (Exhibit 99.1) for specific terms regarding the SPAC structure and potential impact on Allarity Therapeutics, Inc.
- Confirm the relationship and ownership structure between Allarity Therapeutics, Inc. and the newly formed Allarity Acquisition Corp.